Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière

NCT06026696 | Not Yet Recruiting

• 1 other identifier: APHP221076
• Study Type: observational
• Target: 5,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

Neurovascular diseases can cause ischaemic or haemorrhagic strokes. While the most common, such as atherosclerosis are widely studied, others are less well known, such as arterial dissections or cerebral angiopathies. What's more, most studies are limited to a few years' follow-up and the longer-term evolution of patients is less well assessed. Patient follow-up data available in routine practice and specific enrollment through the headache emergencies of the Lariboisière neurovascular intensive care unit (USINV) could provide a particularly rich resource.

Conditions

Ischemic Stroke; Hemorrhagic Stroke

Outcome Measures

Primary Outcomes (1)

• Incidence of a vascular event

  Vascular event is defined as : myocardial infarction, ischaemic or haemorrhagic stroke, recurrence of cerebrovascular disease, systemic embolism, congestive heart disease, vascular or non-vascular death during patient follow-up.

  Up to 5 years

Secondary Outcomes (20)

• Incidence of a vascular event

  Up to 10 years

• Modified Rankin score

  At 3 months

• Modified Rankin score

  At 1 year

• Modified Rankin score

  At 2 years

• Modified Rankin score

  At 3 years

Study Arms (1)

Patients treated for acute cerebrovascular pathology cerebrovascular disease

Other: follow-up

Interventions

follow-up OTHER

Long term follow-up

Patients treated for acute cerebrovascular pathology cerebrovascular disease

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients treated for acute cerebrovascular disease

You may qualify if:

• Adult patients ≥18 years
• Patients admitted to the Neurovascular Intensive Care Unit with acute cerebrovascular disease OR Patients managed for acute cerebrovascular pathology with or without stroke by the Lariboisière neurology team.
• No opposition from the patient to the research and for patients under guardianship or guardianship or lack of capacity to object (severe impairment of cognitive functions, dementia, etc.), no opposition from the legal representative.

You may not qualify if:

• Patient refusing to take part in the study or refusal by the legal representative in the case of patients under guardianship or curatorship
• Patient suffering from a rare neurovascular disease and being followed at the "Centre de référence des maladies vasculaires rares du cerveau et de l'oeil" (CERVCO)

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

MeSH Terms

Conditions

Ischemic Stroke; Hemorrhagic Stroke

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Peggy Reiner, Dr

CONTACT

+33149956525; peggy.reiner@aphp.fr

Jérôme Lambert, Dr

CONTACT

+33142499742; jerome.lambert@u-paris.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 21, 2023
• First Posted: September 7, 2023
• Study Start: September 1, 2023
• Primary Completion (Estimated): September 1, 2033
• Study Completion (Estimated): September 1, 2038
• Last Updated: September 7, 2023

Record last verified: 2023-07